Killer cell immunoglobulin-like receptors influence the innate and adaptive immune responses

Iranian Journal of Immunology

Volumn 4, Issue 2, 2007, Pages 61-78

  Rajalingam, Raja ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HLA; Innate immunity; KIR; NK cells; Polymorphism

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NUCLEOTIDE;

ADAPTIVE IMMUNITY; CLONAL VARIATION; DISEASE PREDISPOSITION; EVOLUTION; GENETIC VARIABILITY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

EID: 34250823477     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
3. French AR, Yokoyama WM. Natural killer cells and viral infections. Curr Opin Immunol. 2003;15:45-51.
4. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002;188:9-21.
5. Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, van Dongen JJ et al. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev. 1998;165:75-86.
6. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol. 2003;3:413-25.
7. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74.
8. Lanier LL. On guard - activating NK cell receptors. Nat Immunol. 2001;2:23-7.
9. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005;5:363-74.
10. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330.
11. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D et al. Genetic control of human NK cell repertoire. J Immunol. 2002;169:239-47.
12. McQueen KL, Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol. 2002;14:615-21.
13. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-93.
14. Long EO, Barber DF, Burshtyn DN, Faure M, Peterson M, Rajagopalan S et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev. 2001;181:223-33.
15. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-23.
16. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-51.
17. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens. 2003;62:79-86.
18. Lanier LL, Bakker AB. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today. 2000;21:611-4.
19. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986; 319:675-78.
20. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-44.
21. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A. 1993;90:12000-4.
22. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity. 1995;2:439-49.
23. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 1997;158:4026-8.
24. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998; 161:571-7.
25. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181:1133-44.
26. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994;180:1235-42.
27. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M et al. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007;178:33-7.
28. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med. 1996;184:505-18.
29. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol. 1996;156:3098-101.
30. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol. 1996;157:3350-6.
31. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med. 1997;185:1523-8.
32. Maenaka K, Juji T, Nakayama T, Wyer JR, Gao GF, Maenaka T et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem. 1999;274:28329-34.
33. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci U S A. 1997;94:6313-8.
34. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature. 2000;405:537-43.
35. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999;189:1093-100.
36. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2:656-63.
37. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006; 4:9.
38. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 Is an IL-2-Regulated NK Cell Receptor That Exhibits Limited Expression in Humans but Triggers Strong IFN-gamma Production. J Immunol. 2003;171:3415-25.
39. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol. 2002;168:6208-14.
40. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol. 2002;168:5047-57.
41. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLAG1-specific receptor. Proc Natl Acad Sci U S A. 1999;96:5674-9.
42. Trundley AE, Hiby SE, Chang C, Sharkey AM, Santourlidis S, Uhrberg M et al. Molecular characterization of KIR3DL3. Immunogenetics. 2006; 57:904-16.
43. Estefania E, Flores R, Gomez-Lozano N, Aguilar H, Lopez-Botet M, Vilches C. Human KIR2DL5 Is an Inhibitory Receptor Expressed on the Surface of NK and T Lymphocyte Subsets. J Immunol. 2007; 178:4402-10.
44. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002; 31:429-34.
45. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol. 1997;27:3095-9.
46. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005; 102:13224-9.
47. Steffens U, Vyas Y, Dupont B, Selvakumar A. Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR), 1998. Tissue Antigens. 1998;51:398-413.
48. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000;97:4778-83.
49. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity. 2001;15:363-74.
50. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-63.
51. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev. 2002;190:40-52.
52. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics. 2002;54:221-9.
53. Williams F, Maxwell LD, Halfpenny IA, Meenagh A, Sleator C, Curran MD et al. Multiple copies of KIR 3DL/S1 and KIR 2DL4 genes identified in a number of individuals. Hum Immunol. 2003;64:729-32.
54. Gomez-Lozano N, Gardiner CM, Parham P, Vilches C. Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B. Immunogenetics. 2002; 54:314-9.
55. Vyas Y, Selvakumar A, Steffens U, Dupont B. Multiple transcripts of the killer cell immunoglobulin-like receptor family, KIR3DL1 (NKB1), are expressed by natural killer cells of a single individual. Tissue Antigens. 1998;52:510-9.
56. Martin MP, Bashirova A, Traherne J, Trowsdale J, Carrington M. Cutting edge: expansion of the KIR locus by unequal crossing over. J Immunol. 2003; 171:2192-5.
57. Yawata M, Yawata N, Abi-Rached L, Parham P. Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol. 2002;22:463-82.
58. Whang DH, Park H, Yoon JA, Park MH. Haplotype analysis of killer cell immunoglobulin-like receptor genes in 77 Korean families. Hum Immunol. 2005;66:146-54.
59. Jiang K, Zhu FM, Lv QF, Yan LX. Distribution of killer cell immunoglobulin-like receptor genes in the Chinese Han population. Tissue Antigens. 2005; 65:556-63.
60. Toneva M, Lepage V, Lafay G, Dulphy N, Busson M, Lester S et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens. 2001;57:358-62.
61. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics. 2001; 52:195-205.
62. Gendzekhadze K, Norman PJ, Abi-Rached L, Layrisse Z, Parham P. High KIR diversity in Amerindians is maintained using few gene-content haplotypes. Immunogenetics. 2006 ;58:474-80.
63. Witt CS, Dewing C, Sayer DC, Uhrberg M, Parham P, Christiansen FT. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation. 1999; 68:1784-9.
64. Denis L, Sivula J, Gourraud PA, Kerdudou N, Chout R, Ricard C et al. Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens. 2005;66:267-76.
65. Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007; 59:1-15.
66. Niokou D, Spyropoulou-Vlachou M, Darlamitsou A, Stavropoulos-Giokas C. Distribution of killer cell immunoglobulin-like receptors in the Greek population. Hum Immunol. 2003;64:1167-76.
67. Norman PJ, Carrington CV, Byng M, Maxwell LD, Curran MD, Stephens HA et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immun. 2002;3:86-95.
68. Rajalingam R, Krausa P, Shilling HG, Stein JB, Balamurugan A, McGinnis MD et al. Distinctive KIR and HLA diversity in a panel of north Indian Hindus. Immunogenetics. 2002;53:1009-19.
69. Santin I, de Nanclares GP, Calvo B, Gaafar A, Castano L, Bilbao JR. Killer cell immunoglobulin-like receptor (KIR) genes in the Basque population: association study of KIR gene contents with type 1 diabetes mellitus. Hum Immunol. 2006;67:118-24.
70. Gutierrez-Rodriguez ME, Sandoval-Ramirez L, Diaz-Flores M, Marsh SG, Valladares-Salgado A, Madrigal JA et al. KIR gene in ethnic and Mestizo populations from Mexico. Hum Immunol. 2006; 67:85-93.
71. Velickovic M, Velickovic Z, Dunckley H. Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations. Immunogenetics. 2006 ;58:523-32.
72. Middleton D, Meenagh A, Gourraud PA. KIR haplotype content at the allele level in 77 Northern Irish families. Immunogenetics. 2007; 59:145-58.
73. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002;169:5118-29.
74. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 2002; 168:2307-15.
75. Garcia CA, Robinson J, Guethlein LA, Parham P, Madrigal JA, Marsh SG. Human KIR sequences 2003. Immunogenetics. 2003; 55:227-39.
76. Rajalingam R, Gardiner CM, Canavez F, Vilches C, Parham P. Identification of seventeen novel KIR variants: fourteen of them from two non-Caucasian donors. Tissue Antigens. 2001; 57:22-31.
77. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol. 2001;166:2992-3001.
78. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006; 203:633-45.
79. VandenBussche CJ, Dakshanamurthy S, Posch PE, Hurley CK. A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. J Immunol. 2006;177:5347-57.
80. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol. 2007;178:235-41.
81. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005;175:5222-9.
82. Maxwell LD, Wallace A, Middleton D, Curran MD. A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey. Tissue Antigens. 2002; 60:254-8.
83. Witt CS, Martin A, Christiansen FT. Detection of KIR2DL4 alleles by sequencing and SSCP reveals a common allele with a shortened cytoplasmic tail. Tissue Antigens. 2000; 56:248-57.
84. Goodridge JP, Lathbury LJ, Steiner NK, Shulse CN, Pullikotil P, Seidah NG et al. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol. 2007; 37:199-211.
85. Goodridge JP, Witt CS, Christiansen FT, Warren HS. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J Immunol. 2003;171:1768-74.
86. Vilches C, Gardiner CM, Parham P. Gene structure and promoter variation of expressed and nonexpressed variants of the KIR2DL5 gene. J Immunol. 2000; 165:6416-21.
87. Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The Protein Made from a Common Allele of KIR3DL1 (3DL1*004) Is Poorly Expressed at Cell Surfaces due to Substitution at Positions 86 in Ig Domain 0 and 182 in Ig Domain 1. J Immunol. 2003;171:6640-9.
88. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol. 2002;169:4253-61.
89. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med. 2003; 197:245-55.
90. Trompeter HI, Gomez-Lozano N, Santourlidis S, Eisermann B, Wernet P, Vilches C et al. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol. 2005;174:4135-43.
91. Dohring C, Samaridis J, Colonna M. Alternatively spliced forms of human killer inhibitory receptors. Immunogenetics. 1996; 44:227-30.
92. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739-51.
93. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. Human NK Cell Education by Inhibitory Receptors for MHC Class I. Immunity. 2006 ;25:331-42.
94. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709-13.
95. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann T et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood. 2007 Mar 28; [Epub ahead of print].
96. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity. 2006; 24:249-57.
97. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105:4416-23.
98. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 1991; 349:329-31.
99. Furukawa H, Yabe T, Watanabe K, Miyamoto R, Miki A, Akaza T et al. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum Immunol. 1999; 60:32-40.
100. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood. 2001; 97:3146-51.
101. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001; 166:6477-82.
102. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052-57.
103. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001;31:3121-27.
104. Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002;46:1763-72.
105. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med. 2005;201:1319-32.
106. Shum BP, Flodin LR, Muir DG, Rajalingam R, Khakoo SI, Cleland S et al. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J Immunol. 2002;168:240-52.
107. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-9.
108. Brown MG, Scalzo AA, Matsumoto K, Yokoyama WM. The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. Immunol Rev. 1997;155:53-65.
109. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature. 1992;358:66-70.
110. Barten R, Trowsdale J. The human Ly-49L gene. Immunogenetics. 1999; 49:731-4.
111. Westgaard IH, Berg SF, Orstavik S, Fossum S, Dissen E. Identification of a human member of the Ly-49 multigene family. Eur J Immunol. 1998;28:1839-46.
112. Welch AY, Kasahara M, Spain LM. Identification of the mouse killer immunoglobulin-like receptor-like (Kirl) gene family mapping to Chromosome X. Immunogenetics. 2003;54:782-90.
113. Glazko GV, Nei M. Estimation of divergence times for major lineages of primate species. Mol Biol Evol. 2003;20:424-34.
114. Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N. Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995;92:532-36.
115. Parham P, Adams EJ, Arnett KL. The origins of HLA-A, B, C polymorphism. Immunol Rev. 1995; 143:141-80.
116. Khakoo SI, Rajalingam R, Shum BP, Weidenbach K, Flodin L, Muir DG et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity. 2000; 12:687-98.
117. Rajalingam R, Hong M, Adams EJ, Shum BP, Guethlein LA, Parham P. Short KIR haplotypes in pygmy chimpanzee (Bonobo) resemble the conserved framework of diverse human KIR haplotypes. J Exp Med. 2001;193:135-46.
118. Rajalingam R, Parham P, Abi-Rached L. Domain shuffling has been the main mechanism forming new hominoid killer cell Ig-like receptors. J Immunol. 2004;172:356-69.
119. Phillips JH, Gumperz JE, Parham P, Lanier LL. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science. 1995; 268:403-5.
120. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S et al. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci U S A. 1996; 93:12433-8.
121. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J Immunol. 2001;166:3923-32.
122. Ugolini S, Arpin C, Anfossi N, Walzer T, Cambiaggi A, Forster R et al. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol. 2001;2:430-5.
123. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 Family Revisited. Annu Rev Immunol. 2005; 23:515-48.
124. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997;40:1106-14.
125. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996;97:2027-37.
126. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM et al. Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000;165:1138-45.
127. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003; 100:9452-7.
128. Snyder MR, Muegge LO, Offord C, O'Fallon WM, Bajzer Z, Weyand CM et al. Formation of the killer Ig-like receptor repertoire on CD4+CD28null T cells. J Immunol. 2002; 168:3839-46.
129. Klein J. Natural history of the major histocompatibility complex. New York: Wiley-Interscience; 1986.
130. [No authors listed]. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 1999;401:921-3.
131. Parham P, Adams EJ, Arnett KL. The origins of HLA-A, B, C polymorphism. Immunol Rev. 1995;143:141-80.
132. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA et al. Nomenclature for Factors of the HLA System, 2004. Hum Immunol. 2005; 66:571-636.
133. Prugnolle F, Manica A, Charpentier M, Guegan JF, Guernier V, Balloux F. Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol. 2005;15:1022-7.
134. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science. 1996; 272:67-74.
135. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872-4.
136. van der Slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003;52:2639-42.
137. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004;173:4273-6.
138. Nikitina-Zake L, Rajalingam R, Rumba I, Sanjeevi CB. Killer Cell Immunoglobulin-like Receptor Genes in Latvian Patients with Type 1 Diabetes Mellitus and Healthy Controls. Ann N Y Acad Sci. 2004;1037:161-9.
139. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001; 193:1159-67.
140. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201:1069-75.
141. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother. 2005 ;54:172-8.
142. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med. 2003;54:491-512.
143. Thomas ED. History, current results, and research in marrow transplantation. Perspect Biol Med. 1995; 38:230-7.
144. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-38.
145. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 1999;5:341-6.
146. Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. 2002;2:231-8.
147. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345:1794-800.
148. Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood. 2001;98:2922-9.
149. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923-30.
150. Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation. 1988;45:714-8.
151. Oudshoorn M, van Leeuwen A, vd Zanden HG, van Rood JJ. Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant. 1994;14:3-8.
152. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17:187-94.
153. Hansen JA, Petersdorf E, Martin PJ, Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev. 1997;157:141-51.
154. Madrigal JA, Scott I, Arguello R, Szydlo R, Little AM, Goldman JM. Factors influencing the outcome of bone marrow transplants using unrelated donors. Immunol Rev. 1997;157:153-66.
155. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med. 1971;134:1513-28.
156. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med. 1971;134:83-102.
157. George T, Yu YY, Liu J, Davenport C, Lemieux S, Stoneman E et al. Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. Immunol Rev. 1997; 155:29-40.
158. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-100.
159. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-9.
160. Yawata M, Yawata N, McQueen KL, Cheng NW, Guethlein LA, Rajalingam R et al. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics. 2002;54:543-50.